INTRODUCTION
Schwartz -Jampel syndrome (SJS, MIM 255800) is a recessively inherited disorder characterized by permanent, generalized muscle stiffness, initially described as myotonia with chondrodysplasia. The disease appears early in life, progressing slowly until adulthood, and has no effect on lifespan (1) . SJS results from hypomorphic mutations in the HSPG2 gene encoding perlecan (2) . Perlecan is a complex (800 kDa) heparan sulphate proteoglycan (HSPG) secreted into all basement membranes (BM) and involved in cell adhesion, growth factor signalling and BM maintenance (3) . Thirty HSPG2 mutations have been described in SJS, including missense and truncating mutations, which are found along the entire length of HSPG2 (4, 5) . The hypomorphic effect of these mutations results in a decrease in the amount of apparently full-length perlecan in BMs, but not to the complete absence of this protein. Indeed, the complete absence of perlecan in humans leads to dissegmental dysplasia, SilvermanHandmaker type (DDSH, MIM 224410)-a type of chondrodysplasia lethal at birth (6) . It has been suggested that a gene dosage effect accounts for the difference between SJS and DDSH, as no genotype-phenotype relationship could be established.
The muscle stiffness in SJS is permanent and leads to a characteristic 'mask-like' face with blepharospasm and pursed lips. It is associated with the recording of complex repetitive discharges (CRDs) at rest on electromyography (EMG) (S. Nicole et al., manuscript in preparation). This spontaneous activity is probably pre-synaptic in origin as it is abolished by the blockade of neuromuscular transmission with curare, leading to the classification of SJS as a form of neuromyotonia (7, 8) . The persistence of this activity during sleep and anaesthesia suggests a peripheral origin. Perlecan is present in the muscle and nerve BMs. It is more abundant at the neuromuscular junction (NMJ), where it is crucial for anchoring the collagen-tailed form of acetylcholinesterase (AChE) to the synaptic BM (9, 10) . AChE limits the duration of the synaptic response by hydrolysing acetylcholine (ACh). It has therefore been suggested that SJS neuromyotonia may result from endplate AChE deficiency. Consistent with this hypothesis, we observed very low levels of endplate AChE in one SJS patient (S. Nicole et al., manuscript in preparation). However, endplate AChE deficiency has also been reported in congenital myasthenia due to mutations in COLQ, which encodes the collagen-tail of endplate AChE (11, 12) . This form of myasthenia is clearly different from SJS, as it is characterized by muscle fatigability without CRDs on EMG. Moreover, the physiological characteristics of endplate AChE deficiency-repetitive and decrementing compound muscle action potentials (CMAPs) in response to single and repetitive nerve stimulations, respectively-are not recorded in SJS (S. Nicole et al., manuscript in preparation). The physiological significance of the partial endplate AChE deficiency in SJS therefore remains unknown.
We aimed to develop a mouse model of SJS for studies of SJS neuromyotonia. We introduced the p.C1532Y substitution, corresponding to a familial SJS missense mutation, into the mouse Hspg2 gene for three reasons: (i) this mutation is homozygous in siblings with severe features of SJS (2); (ii) the C1532 residue is conserved across species and is required for a well-defined pattern of disulphide bonds in domain III of perlecan and (iii) it is associated with the intracellular retention of mutant perlecan, decreasing extracellular perlecan amount (4) . We also aimed to investigate the possibility of a dosage effect of perlecan in mammals, by deriving two lines from the initial strain: one with and the other without the selectable marker Neo for the down-regulation of perlecan gene expression. An independently generated strain of p.C1532Y mice that did not reproduce SJS neuromyotonia was recently described (13) . It was concluded in this previous study that the p.C1532Y substitution had no effect in mice because it did not cause chondrodysplasia when present in isolation. Our results contrast with these data since our two mutant lines developed a neuromuscular phenotype mimicking SJS at the macroscopic and microscopic levels. The mutant phenotype induced by p.C1532Y was worsened by Neo, consistent with a dosage effect. We further demonstrated the occurrence of endplate AChE deficiency in the absence of perlecan unrelated to major muscle or NMJ disorganization. Finally, we showed that endplate AChE deficiency may contribute to SJS neuromyotonia by potentiating muscle force, but probably not by inducing spontaneous activity at rest.
RESULTS

Generation of a series of alleles with decreasing levels of perlecan secretion
We introduced the c.4595G.A point substitution, encoding p.C1532Y, into exon 36 of the mouse Hspg2 gene by homologous recombination (Fig. 1A) . We established two mouse lines to test for a gene dosage effect: Hspg2 C1532Y-Neo containing the selection cassette Neo in intron 36, and Hspg2 C1532Y derived from Hspg2 C1532Y-Neo by mating with CMV-Cre transgenic mice. The heterozygous mice of both lines were normal and fertile, and homozygous mutant mice were obtained at the expected frequency.
We first checked whether the p.C1532Y substitution in mice led to a pattern similar to that observed in humans. Immunostaining of transverse muscle sections with antibodies against domains I, IV and V of perlecan demonstrated smaller amounts of apparently full-length perlecan in the BMs of 2-month-old Hspg2 C1532Y and Hspg2 C1532Y-Neo homozygous mutant mice than in those of control mice (Fig. 1B) . We investigated the origin of this decrease by analysing primary fibroblast cells obtained from skin biopsies. The extracellular network formed by perlecan was less extensive in Hspg2 C1532Y than in control cells and was almost absent from Hspg2 C1532Y-Neo cells. Furthermore, membrane permeabilization with 0.1% Triton X-100 before immunostaining showed the intracellular accumulation of perlecan in Hspg2 C1532Y and Hspg2 C1532Y-Neo cells (Fig. 1B) . This accumulation did not result from a failure to form extracellular matrix, as the fibronectin network was normal (data not shown). Dot-blot quantification of perlecan present in conditioned culture media confirmed that perlecan secretion in Hspg2 C1532Y samples was lower than that in controls by a factor of 1.8 (n ¼ 3; t-test, P , 0.001; Fig. 1C 
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C1532Y samples by a factor of 1.4 (n ¼ 3; t-test, P ¼ 0.041). Consistent with the residual secretion of full-length perlecan, a weak band of the expected size was observed on western blot analyses of conditioned culture media (Fig. 1D) .
We further analysed the effect of c.4595G.A and Neo on Hspg2 mRNAs by RT -PCR analysis. Quantitative real-time (QRT) PCR, using an assay directed against Hspg2 exons 11-12, showed no significant decrease in Hspg2 RNA levels of muscle samples from 2-month-old Hspg2 C1532Y mutants compared with controls (n ¼ 3; t-test, P ¼ 0.1; Fig. 2A ). RT -PCR with primers binding to exons 33 and 38 detected no abnormal splicing events and confirmed the production of a full-length Hspg2 mRNA containing the c.4595G.A substitution (data not shown). In contrast, Hspg2 mRNA levels in Hspg2 C1532Y-Neo muscle samples were 44% lower than those in Hspg2 C1532Y samples (n ¼ 3; t-test, P ¼ 0.003). The amount of Hspg2 mRNA with the c.4595G.A substitution generated from the Hspg2 C1532Y-Neo allele was estimated to be 36% that generated from the Hspg2 C1532Y allele, based on semiquantitative analyses (n ¼ 6; t-test, P ¼ 0.003; Fig. 2B ). Neo contains cryptic splice sites when positioned in the same orientation as the targeted gene (14) . We therefore searched for splicing events between Neo and flanking Hspg2 exons in Hspg2 C1532Y-Neo muscle samples. RT-PCR analyses detected Fig. S1 ). Interestingly, a progressive neuromuscular phenotype was observed from the age of 2 months, with delayed opening of the eyelids and stiffened flexion of hind limbs when the animal was suspended by the tail (Fig. 3A) . This phenotype was observed in both lines but progressed more slowly in Hspg2 C1532Y mice: 54% of Hspg2 C1532Y-Neo mutants had a severe phenotype (constantly closed eyes and long flexions of hind limbs), 31% were mildly affected (partially closed eyes and mild flexions) and 15% did not appear to be affected at the age of 6 months. At the same age, 54% of Hspg2 C1532Y mutants had developed a mild phenotype, but none was severely affected (x 2 test, P ¼ 0.007). Consistent with their more severe phenotype, the lifespan of Hspg2 C1532Y-Neo mice was shorter than that of Hspg2 C1532Y mice (n ¼ 10; log rank test, P , 0.001), with the lifespan of Hspg2 C1532Y mice not significantly different from that of controls (Fig. 3B) .
EMG was carried out in Hspg2 C1532Y-Neo mutants, to confirm the occurrence of muscle hyperactivity. Spontaneous activity resembling CRDs was recorded at rest in all mutant muscles tested (gastrocnemius, biceps brachialis, rectus abdominus) other than the diaphragm (Fig. 3C ). This activity was stable in amplitude (400 mV on average) and frequency, up to 250 Hz, and lasted up to 30 s. It was induced by movements of the recording needle in all limb muscles and was constant in head muscles (buccinator and levator palpebrae muscles), highlighting the relationship between spontaneous activity and the severity of muscle stiffness. Unlike rest EMG, CMAPs were normal. We observed no repetitive or decrementing responses following single or repetitive (3 Hz) supramaximal nerve stimulation (data not shown).
Overall, the homozygous mutants had a phenotype mimicking SJS, with chondrodysplasia, muscle stiffness (particularly pronounced in the facial area) and spontaneous activity at rest on EMG. The difference in phenotype between the two lines was consistent with a dosage effect, with an inverse correlation between severity and the amount of perlecan secreted into BMs.
The presence of smaller amounts of perlecan in extrasynaptic BMs does not lead to major damage to myofibres Mild and non-specific histological changes in muscle are reported in SJS patients, with variability in the size of myofibres, centralized nuclei, vacuoles and a predominance of slow type 1 fibres with grouping of fast type 2 fibres (1). We searched for similar changes in mutant mice, and observed variability in fibre size, centralized nuclei and a predominance of type 1 fibres, with groups of type 2 fibres in the soleus of 6-month-old Hspg2 C1532Y-Neo mutants (Fig. 3D) . Despite the presence of centralized nuclei suggestive of myofibre regeneration, signs of acute muscle degeneration-regeneration processes, such as the infiltration of mononuclear cells and necrotic fibres, were not seen. No histological changes were seen in the other Hspg2 C1532Y-Neo muscles studied. None of the Hspg2 C1532Y muscles, including the soleus, appeared to be affected at any age.
Perlecan is important for the maintenance of BMs subject to mechanical stress and is required for the initiation and stabilization of sarcomere unit organization in Caenorhabditis elegans and zebrafish (15 -17) . Muscle degeneration -regeneration might therefore be expected in SJS, and we investigated this possibility in Hspg2 C1532Y-Neo mice. We first ruled out the possibility of the changes observed being developmental defects, as they were not observed in 2-month-old mutants. Evans blue dye injection showed no signs of myofibre necrosis in the soleus of 6-month-old Hspg2 C1532Y-Neo mutants (data not shown). We studied the expression of BM and dystrophin -glycoprotein complex (DGC) components, as the DGC is essential for the mechanical stability of the sarcolemma, linking the actin cytoskeleton to the BM (18) . Immunostaining revealed no marked change other than the up-regulation of muscle agrin, another HSPG found in the extrasynaptic BM (Supplementary Material, Fig. S2A ) (19) . Finally, the organization of sarcomeres was investigated by immunostaining for a-actinin, the actin-binding protein present at the Z-line, on dilacerated myofibres. This organization appeared to have been preserved, with a typical striated pattern observed (data not shown). These findings are not consistent with major muscle degeneration events in SJS, and indicate that such events were not involved in the pathogenesis of SJS neuromyotonia.
Partial endplate AChE deficiency without major NMJ disorganization in Hspg2
C1532Y and Hspg2 C1532Y-Neo mutants Endplate AChE deficiency is thought to be responsible for SJS neuromyotonia because perlecan is essential for the anchoring of the collagen-tail form of AChE to the synaptic BM (9,10). These lower concentrations were associated with smaller amounts of perlecan in the synaptic BM in Hspg2 C1532Y and Hspg2 C1532Y-Neo mice (Fig. 4A ). AChE is present in three forms in muscle: collagen-tailed AChE anchored to the synaptic BM, prima-anchored AChE bound to the membrane and soluble (globular) AChE (20) . The collagen-tailed form is the major AChE form at the NMJ. It consists of three ColQ units, which attach tetramers of AChE to the BM by binding to perlecan, itself attached to a-dystroglycan (21) . Sedimentation velocity analyses confirmed the specific loss of collagen-tailed AChE in Hspg2 C1532Y and Hspg2 C1532Y-Neo mutants, with levels reduced to 52 (t-test; P ¼ 0.001) and 18% (t-test; P , 0.001) of controls, respectively (Fig. 4B ). The decrease in collagentailed AChE was more pronounced in Hspg2 C1532Y-Neo compared with Hspg2 C1532Y (t-test, P ¼ 0.001). Other forms of AChE were not statistically modified compared with controls. This decrease probably reflected the loss of endplate AChE, because collagen-tailed AChE was detected only in muscle extracts containing NMJs in studies of wild-type mice (E. Krejci and V. Bernard, unpublished data). The possibility of the observed decrease at morphological level being due to redistribution of the collagen-tailed AChE along the myofibres was also excluded.
Denervation -reinnnervation processes occurred in SJS patients, potentially accounting for endplate AChE deficiency because synaptic AChE transcript levels are down-regulated by denervation (S. Nicole et al., manuscript in preparation; 22). We investigated this possibility in Hspg2 C1532Y-Neo mutants. QRT -PCR detected no decrease in Ache and Colq gene expression in 2-month-old mutants (data not shown). Fluorescent double-staining of nerve terminals and AChE further excluded the possibility of endplate AChE deficiency being due to denervation, as weaker AChE staining was observed in well-innervated NMJs (Fig. 5A) . Double-staining of nerve terminals and post-synaptic AChRs demonstrated the partial denervation of 12% of NMJs (n ¼ 153) in 8-month-old mutants, with thin terminal nerves suggestive of nerve sprouting (Fig. 5B ). This proportion was far lower than the 100% of NMJs showing AChE deficiency. Immunostaining of terminal Schwann cells (tSCs), the third cellular component of the NMJ, showed extension of cellular processes in 19% of mutant NMJs (n ¼ 16; Fig. 5C ), demonstrating the occurrence of reinnervation, as tSCs cells develop processes to guide nerve sprouting (23) .
In addition to denervation -reinnervation processes, we observed NMJ remodelling in 96% of mutant NMJs, associated with a streaky pattern, and weaker pretzel-like organization of nAChRs than for controls at the age of 8 months (n ¼ 79; 1.56 + 0.16 branching points versus 5.15 + 0.28 in controls, P ¼ 0.045; Supplementary Material, Fig. S4A ). Mutant NMJs also covered only 58% the area of control NMJs (391 + 42 versus 676 + 64 mm 2 , respectively; t-test, P ¼ 0.02). The diameter of myofibres was smaller in mutants (38.3 + 2.3 versus 51.2 + 3.4 mm in controls; t-test, P ¼ 0.034), maintaining the proportionality between NMJ area and fibre diameter, probably to preserve the efficiency of neuromuscular transmission (Supplementary Material, Fig. S4B ) (24) . We investigated the distribution and level of major NMJ components by immunostaining, to determine Fig. S2B ). MuSK and dystroglycan, which attach AChE -ColQ and AChE -ColQ -perlecan complexes, respectively, to the synaptic sarcolemma, were unaffected (10, 25) . NMJ ultrastructure also appeared to be conserved (n ¼ 31 from five mutants and n ¼ 11 for controls; Supplementary Material, Fig. S4C ). In particular, events seen in ColQ-deficient mice, such as invasion of the synaptic cleft by tSCs and post-synaptic necrosis, were not observed (26) . Overall, our data show that the endplate AChE deficiency resulted from a decrease in the amount of perlecan at the NMJ rather than any major NMJ disorganization.
Endplate AChE deficiency leads to the potentiation of muscle force, with a prolonged decay time of endplate potentials
The association of endplate AChE deficiency with congenital myasthenia called into question the physiological significance of endplate AChE deficiency in SJS. We addressed this question by studying 8-month-old Hspg2 C1532Y-Neo mutants. We first studied the isometric contractile properties of the TA in situ in response to nerve stimulation, as AChE-null mice display potentiation with tetanic fade of muscle force (27) . The specific maximal tetanic force (sP0, maximal tetanic force related to muscle mass) of mutants was not lower than those of controls, excluding muscle weakness (Table 1) . Absolute (Pt) and specific (sPt) twitch forces were found to be potentiated in mutants, resulting in a higher twitch/ tetanus ratio (Pt(%P0)), time to peak tension (CT) and halfrelaxation time ( 1 2 RT). Potentiation was not limited to twitch forces, as specific submaximal tetanic force at 25 Hz (sP25) was 1.2 times higher in mutants than in controls. Moreover, analysis of the tetanic tension during a 500 ms nerve stimulation train showed a tetanic fade at low (12.5 and 25 Hz) but not at high (50 and 100 Hz) frequencies (Fig. 6A) . Despite these modifications, the relaxation velocity, calculated from the tetanic force at 100 Hz, was unaffected. We measured muscle force evoked by direct muscle stimulation after blockade of post-synaptic AChRs with gallamine triethiodide (a synthetic non-depolarizing drug) to exclude a post-synaptic origin of the force changes. Twitch/tetanus ratio decreased from 44.8 + 5.7% in response to nerve stimulation to 24.2 + 1.6% in response to direct muscle stimulation (n ¼ 3; t-test, P ¼ 0.048,) in mutants, whereas it did not significantly change in controls (30.7 + 8.4% versus 19.7 + 1.9%; t-test, P ¼ 0.251). Tetanic fade at 12.5 and 25 Hz were no more recorded in Hspg2 C1532Y-Neo mutants when muscle stimulation was applied (Fig. 6A) . These results agreed with endplate AChE loss as being at the origin of the muscle force changes.
We also studied isolated hemidiaphragm muscles ex vivo, as the diaphragm displayed no spontaneous activity on EMG, despite being deficient for endplate AChE. Supramaximal 
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phrenic nerve stimulation evoked potentiated twitch and tetanic responses, depending on the stimulation frequency, as for TA. The twitch/tetanus ratio was up to 30% higher in mutant muscles than in controls at low frequencies (10 -60 Hz), and was similar to that in controls at higher frequencies (up to 100 Hz, Supplementary Material, Fig. S5 ). The potentiation was not due to a difference in muscle weight, as it was similar in mutants and controls (144.9 + 25.5 and 142.5 + 6.4 g, respectively, t-test, P ¼ 0.91). However, tetanic fade was not observed in any case, regardless of the frequency used for nerve stimulation, in contrast to what was observed for the TA of Hspg2 C1532Y-Neo mutants and diaphragm of AChE-null mice (28) . The comparison of the maximum forcetime integral of twitch responses evoked by nerve stimulation to responses evoked by direct muscle stimulation (after suppressing neuromuscular transmission with 10 mM tubocurarine) revealed that twitch force-time integrals resulting from direct muscle stimulation were significantly reduced when compared with nerve stimulation in Hspg2 C1532Y-Neo mutants (389.0 + 64.4 versus 539.6 + 47.7 mNms; n ¼ 3; t-test, P ¼ 0.049). Under the same conditions, no significant difference was observed in controls (P ¼ 0.386).
We further evaluated neuromuscular transmission using intracellular recordings on isolated hemidiaphragm muscles in the presence of physiological Ca 2þ concentrations (2 mM). Miniature endplate potentials (MEPP) and endplate potentials (EPP) were found to be prolonged in mutants when compared with controls, as expected for lower levels of endplate AChE activity (Fig. 6B) (29) . Spontaneous MEPPs decayed 1.3 times more slowly in mutant NMJs than in controls at similar resting membrane potentials (range 260 to 270 mV; Table 2 ). Fullsized EPPs evoked by nerve stimulation at low frequency (0.1 Hz) also decayed more slowly in mutant NMJs than in control NMJs. Consistent with the partial, as opposed to complete AChE deficiency, mutant NMJs remained sensitive to AChE inhibition with 3 mM neostigmine. This treatment prolonged the half-decay time of MEPPs from 2.3 + 0.08 to 3.4 + 0.2 ms (n ¼ 30). The prolonged decay time of EPPs and MEPPs in mutant NMJs probably reflects endplate AChE deficiency, even though EPPs and MEPPs give no direct measurement of the underlying change in conductance, because of the passive electrical properties of myofibres. MEPP frequency was significantly decreased, unlike the quantal content of EPPs (Table 2 ). These changes suggest that there are mechanisms compensating for endplate AChE deficiency, preserving neuromuscular transmission.
Our data demonstrate a physiological effect of endplate AChE decrease with prolonged EPPs, which is probably responsible for the potentiation of isometric muscle tension evoked by nerve stimulation at low frequencies in TA and diaphragm. These changes may result from the slower disappearance of ACh within the synaptic cleft, which may have induced multiple myofibre action potentials due to repetitive binding to post-synaptic nAChRs. (13), but also in muscle stiffness with spontaneous activity on EMG. Using these models, we demonstrated for the first time that partial endplate AChE deficiency occurs as a result of synaptic perlecan deficiency in SJS, whereas myofibre and NMJ organizations are preserved. Moreover, we showed that the AChE deficiency exerts a physiological effect on neuromuscular transmission, which is most likely at the origin of the muscle force potentiation and fatigability evoked by low frequencies of nerve stimulation. However, our data suggest that endplate AChE deficiency is not sufficient to induce spontaneous activity on EMG. We are confident that our mutants constitute accurate models of SJS for four reasons. First, the phenotype resulted from the intracellular retention of mutant perlecan in the Hspg2 C1532Y line, leading to the secretion of smaller amounts of perlecan into the BMs, as in human cells homozygous for the orthologous mutation (4). Second, muscle stiffness was most marked for the head of the mutant mice, mimicking the 'mask-like' face of SJS patients. Third, spontaneous muscle activity, similar to the CRDs recorded for SJS patients, was recorded on EMG. Fourth, the muscle changes observed, with partial endplate AChE deficiency and NMJ remodelling with denervation-reinnervation and no major ultrastructural abnormalities, mimicked those reported to be associated with truncating HSPG2 mutations in humans (S. Nicole et al., manuscript in preparation). One difference was the progression of the disease, as it worsened with ageing in mice. The reason for this difference remains unclear. However, the patients homozygous for the p.C1532Y mutation were 15 and 18 years old at their most recent check-up, and the progression of the disease caused by this mutation in adults therefore remains unclear. Neuromyotonia would also be expected to lead to prolonged muscle relaxation, as reported in two patients with SJS (8). Our measurements of isometric tension in the TA in situ detected no prolongation of muscle relaxation in mutants, despite the presence of spontaneous activity on EMG. This suggests 'latent' neuromyotonia in our mutant mice, i.e. muscle hyperactivity that does not lead to disabling muscle stiffness (30) , and is reminiscent of SJS cases with mask-like expression being the major or only sign of SJS neuromyotonia (4).
It was recently suggested that the p.C1532Y substitution acts as a splicing mutation in humans, as it does not induce severe chondrodysplasia in mice (13) . Our results contrast with these findings, as our homozygous Hspg2 C1532Y mutants developed a phenotype mimicking SJS at the macroscopic and microscopic levels. The p.C1532Y substitution was not associated with abnormal splicing events in mice (this study), or in lymphoblasts and fibroblasts derived from patients homozygous for p.C1532Y (S. Nicole, unpublished data). However, we observed intracellular accumulation of the mutant p.C1532Y protein, with lower than normal extracellular perlecan levels, as reported in humans (4) . Domain III consists of modules with a uniform disulphide bridge pattern based on eight cysteine residues, giving rise to four loops (31) . The p.C1532 residue is involved in this pattern, and its substitution probably results in the generation of a misfolded protein, which is retained within cells by quality control pathways (2) . Consistent with this hypothesis, p.C1532Y prevents the secretion of recombinant mouse domain III by mouse cells (13) . The different effects of p.C1532Y in our lines and in those previously published may result from the different ages of the animals studied. Rodgers' group studied mice between birth and the age of 2 months (13). We studied adult mice and showed that they developed a neuromuscular phenotype with ageing. The different genetic backgrounds used (mixed 129Sv-R1 versus mixed 129Sv-BL/6J for our line) may also have contributed to the divergence of the results obtained, as genetic background may modify the phenotype resulting from a single mutation (32) .
We found that the PGK-Neo cassette worsened, but did not induce, the abnormal phenotype, by decreasing the production of mutant RNA. The lower levels of Hspg2 RNA generated from the Hspg2 C1532Y-Neo allele were probably due to the presence of the transcription termination signal of PGK-Neo in addition to the splicing events we observed between Neo and Hspg2. The observed Hspg2-Neo hybrid mRNAs were predicted to encode truncated forms of perlecan. They were probably subject to nonsense-mediated decay, because of the premature stop codons they contain. This may account for the smaller amounts of Hspg2 mRNA detected in Hspg2 C1532Y-Neo samples with a probe binding 5 0 end to the mutation. The lower levels of secretion of the mutant perlecan in Hspg2 C1532Y-Neo mice were associated with a phenotype more severe than that of Hspg2 C1532Y mice, suggesting dosage effect. A dosage effect associated with perlecan mutations has already been reported in Drosophila melanogaster and C. elegans, with phenotypes ranging from larval lethality to adult viability, depending on residual perlecan levels (1). Dosage effects may account for the difference between our lines and the lines of Rodgers' group. They may also account for the difference in severity for each mutant mouse. Indeed, our mutant lines were not established in a homogeneous genetic background, and the level of residual mutant perlecan secretion may vary between mutant mice. Establishing the same p.C1532Y mutation into different genetic backgrounds, then comparing the levels of perlecan and the severity of bone and muscle phenotype in mutants would resolve this issue. Eventually, it would allow to search for genetic factors modifying the expression of the disease. SJS clinical signs are also of variable severity in humans, ranging from almost asymptomatic neuromyotonia without bone changes to severe forms requiring the use of a wheelchair (33, 34) . The demonstration of a dosage effect in mammals is important, as it may open new possibilities for treatment in humans.
Perlecan is involved in BM maintenance in mammals, and is crucial for sarcomere organization in C. elegans and zebrafish (15 -17) . However, no muscle dystrophy with major muscle degeneration processes is observed in either humans or mice with SJS, consistent with the lack of muscle weakness detected on muscle force analyses. Perlecan is probably present in sufficient quantities to assume these muscle functions. Alternatively, the loss of perlecan may be compensated by agrin, probably produced in larger amounts due to denervation-reinnervation (19) . The extrasynaptic isoform of agrin, which is not involved in NMJ formation, interacts with transmembranous receptors and BM components, and can rescue muscle dystrophy resulting from laminin a2 mutations (35) . Crossing our perlecan-mutant line with mice deficient for the extrasynaptic form of agrin would determine whether this HSPG compensates for the loss of perlecan. Perlecan deficiency results in the redistribution of myofibre types, as observed in both mutant mice and SJS patients (N. Romero and M. Fardeau, unpublished observations). Our results demonstrated that this abnormal pattern was not developmental, as it appeared with age in mice. Instead, it probably resulted from denervation-reinnervation processes, as the redistribution of fibre types occurs after the partial crushing of nerves (36) . The soleus was the only muscle studied to display a mosaic pattern. Thus, the grouping of type 2 myofibres may result from the sprouting of adjacent intact motor axons, whereas the predominance of type 1 myofibres may reflect the higher sprouting efficiency of motor nerve terminals innervating slow myofibres (37) . This study confirms that partial endplate AChE deficiency is a consistent feature of SJS. The accumulation of AChE at the NMJ results from a complex process involving the production of larger amounts of AChE and ColQ transcripts by subsynaptic nuclei and multiple interactions within the synaptic BM and sarcolemma (38) . Our results demonstrate that the endplate AChE deficiency in SJS is related to the decrease in synaptic perlecan levels rather than myofibre degeneration, NMJ remodelling or denervation. It remains unclear where the binding interaction between perlecan and the AChE -ColQ complex occurs. Preliminary studies have suggested that the AChE -ColQ -perlecan complex assembles within the myofibre, at least during development (38) . The huge decrease in endplate AChE levels may therefore result from a failure to secrete this complex, followed by intracellular degradation when perlecan is itself poorly secreted. Alternatively, the AChE -ColQ complex may be secreted and then diffused or degraded when not retained within the synaptic BM. Studies on perlecan-null cells are required to address this question.
In addition to highlighting the role of perlecan in endplate AChE anchoring, our results show a correlation between NMJ remodelling, denervation -reinnervation and decreases in perlecan levels. These changes may result from or reflect an adaptation to endplate AChE deficiency, as they are also observed in ColQ-null mice (26) . However, they may also indicate a role for perlecan in NMJ maturation. No changes to the NMJ other than AChE deficiency were reported in perlecan-null embryos at E18, excluding an essential role for perlecan in NMJ formation (9) . However, NMJ maturation occurs after birth, and could not be studied in perlecan-null mice due to embryonic lethality. NMJ maturation includes transformation of the rounded plaque into an elaborated pretzel-like shape of pre-and post-synaptic elements, with the formation of synaptic folds (39) . The DGC plays an important role in these steps. NMJ remodelling with utrophin and AChE deficiencies are observed in mice deficient in dystroglycans (40) . A major streaky pattern of nAChRs with a patchy distribution and undefined borders of gutters is observed in mice lacking a-dystrobrevin and a-syntrophin (41, 42) . These observations suggest that perlecan may be involved in NMJ maturation, as it is a major binding partner of a-dystroglycan (43) .
AChE deficiency at the NMJ has already been linked to congenital myasthenia with loss-of-function mutations in COLQ (11, 12) . The clinical and physiological divergence between this form of myasthenia and SJS raised questions about the physiological effect of the endplate AChE deficiency in SJS. We demonstrated that the endplate AChE deficiency is of physiological significance, prolonging miniature and nerveevoked EPPs and most likely potentiating muscle force. However, these changes were not associated with repetitive or decrementing responses on EMG. Nevertheless, we observed tetanic fade at 12.5 and 25 Hz in the TA of Hspg2 C1532Y-Neo mutants. These frequencies are within the range of physiological frequencies (14 -70 Hz in mice), suggesting that muscle fatigability may occur in SJS. The disappearance of tetanic fade at higher frequencies and its absence from the diaphragm probably result from pre-and post-synaptic modulations to compensate for ACh accumulation in the synaptic cleft. The preserved ultrastructural organization of NMJs may also account for the well sustained nerve-evoked muscle contraction at high frequencies in SJS (24, 26, 28) .
Finally, could SJS neuromyotonia result from ACh accumulation in the synaptic cleft induced by endplate AChE deficiency? A distinction should be made between muscle stiffness and spontaneous activity on EMG at rest when addressing this question. Our data demonstrate potentiation of muscle force and increased twitch half-relaxation time, which most likely result from the endplate AChE deficiency documented by the prolongation of EPPs. Endplate AChE deficiency may contribute to SJS muscle stiffness through this potentiation. However, the endplate AChE deficiency does not appear to be responsible for the spontaneous activity observed on EMG since the diaphragm was devoid of spontaneous activity despite the demonstration of physiological AChE deficiency. Preliminary observations have indicated that spontaneous activity in Hspg2 C1532Y-Neo mutants originates from the distal motor nerve (A. Echaniz-Laguna and S. Nicole, unpublished data). Perlecan is present in axonal BMs. Axonal changes may therefore result from decreases in perlecan levels, accounting for spontaneous activity on EMG in isolation or together with endplate AChE deficiency. One plausible hypothesis is a dysfunction of pre-synaptic potassium channels, a known cause of neuromyotonia (44) . Our mouse models will be valuable tools for investigating these hypotheses, for gaining insight into SJS neuromyotonia, and for testing new therapeutic approaches.
MATERIALS AND METHODS
Mouse lines
The mutant mouse lines were generated from two independent targeted ES cell clones established at the ICS-MCI (Mouse Clinical Institute, Illkirch, France) by homologous recombination. Briefly, two fragments encompassing introns 33 to 37 of the Hspg2 gene were amplified by long-range PCR from 129Sv genomic DNA for introduction of the c.4595G.A (p.C1532Y) point mutation into exon 36, and were inserted Reverse transcription-polymerase chain reaction
Total RNA was extracted from mouse quadriceps or TA using Trizol reagent (Invitrogen TM ) and was reverse-transcribed with random hexamers, according to the manufacturer's protocol (Thermoscript TM RT -PCR System, Invitrogen TM ). The presence of the c.4595G.A mutation in Hspg2 was confirmed by sequencing cDNAs after PCR amplification with primers binding within Hspg2 exons 33 and 38 or 35 and 41. Semiquantitative PCR and TseI digestion were done using muscle samples of 2-month-old heterozygous mice. Quantization of digested products was performed using the free Image J software. Splicing events between Neo and Hspg2 were studied using primers binding within exons 35, 37 and Neo, respectively (all primer sequences are available on request). The RT -PCR products were sequenced using the BigDye v3.1 Terminator kit (Applied Biosystems) and an automated sequencer (ABI3100, Applied Biosystems).
QRT -PCR analyses were performed using a TaqMan RealTime PCR detection system (ABI7000, Applied Biosystems). The products of the reverse transcription reaction (100 mg), QPCR Mastermix (Eurogentec) and the prevalidated TaqMan w Gene expression assays (Applied Biosystems) Hs99999901_s1 (universal 18S RNA, used for the normalization of the results), Mm00464544_g1 (Hspg2), Mm 00477275_m1 (Ache), and Mm01211248_m1 (Colq) were used according to the manufacturers' protocols. Colq and Ache probes were considered to detect all mRNA isoforms as they bind to sequences encoding the triple helical domain of ColQ and the esterase domain of AChE, respectively. All samples were measured in triplicate and the results were expressed as 2 2DDCt to determine the amount of Hspg2 mRNA relative to controls (User Bulletin #2 ABI PRISM 7700, Applied Biosystems, December 1997).
Cell culture
Primary fibroblast cells were established from mouse skin biopsy specimens, as previously described (4).
Biochemistry
For dot-blotting, 5.10 4 fibroblasts were incubated in serum-free medium for 2 days. Serial dilutions of conditioned medium were applied to nitrocellulose membrane (Amersham) using a dot-blot apparatus (BioRad Laboratories). The membrane was blocked with non-fat milk in phosphate-buffered saline (pH 7.4; PBS) and incubated with monoclonal antibodies to perlecan domain IV, or polyclonal antibodies to fibronectin (Sigma-Aldrich) as control of equal deposition of conditioned medium. After intensive washings, membranes were incubated with secondary horseradish peroxidase-conjugated antibodies (Jackson Immunoresearch laboratories). Chemiluminescence (PerbioScience) was detected by autoradiography. Dot quantification was performed using ImageJ software, and perlecan protein levels were normalized to fibronectin.
Western blotting for perlecan was carried out as previously described (45) . Briefly, proteoglycans were purified by ion-exchange chromatography from conditioned culture media. Proteins (7 mg) were digested overnight at 378C with 4 mU of heparitinase (Seikagaku Corporation) in 100 mM sodium acetate buffer, pH 7.0, 10 mM calcium acetate, 0.1% bovine serum albumin (BSA) with protease inhibitors (10 mM EDTA, 10 mM ethyl maleimide, 1.25 mM phenylmethanesulfonyl fluoride, 1 mM pepstatin A). Digestion products were separated by SDS-PAGE and blotted onto a membrane, which was then processed as for dot-blotting.
Sucrose gradient sedimentation was performed on TA ground in liquid nitrogen. The powder was homogenized in 25 mM Tris-HCl, pH 7.4, 10 mM EDTA, 800 mM NaCl, and 1% CHAPS supplemented with protease inhibitors. Sedimentation analyses of AChE forms were carried out with 5 -20% (wt/vol) sucrose gradients containing 50 mM Tris -HCl, pH 7, 10 mM MgCl 2 , 800 mM NaCl and 1% Brij-97. We collected 48 fractions from each gradient, which were assayed for AChE activity in the presence of 50 mM tetraisopropylpyrophosphoramide (Iso-OMPA, Sigma-Aldrich). Optical density at 414 nm was determined several times for each fraction. The area of the peaks was used to estimate the quantity of collagen-tailed form of AChE in muscle extracts.
Muscle specimens
Fresh skeletal muscles were snap-frozen in liquid nitrogencooled isopentane (Sigma-Aldrich) at 21608C and stored at 2808C for immunostaining on transverse (8 mm) or longitudinal (20 mm) cryosections. For whole-mount preparations, mice were transcardially perfused with a mixture of 2% paraformaldehyde (PFA, Sigma-Aldrich) and 0.2% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), and dissected muscles were post-fixed by overnight incubation in 2% PFA. EDL of transcardially perfused mice was post-fixed by overnight incubation in 2% PFA for electronic microscopy. The NMJs were identified by detecting nAChRs with a-bungarotoxin (a-BTX) coupled to biotin (Molecular Probes), using a pre-embedding immunogold method. Muscles were treated with 1% osmium, dehydrated and embedded in resin. Ultrathin sections were cut, stained with lead citrate and examined in a Philips CM120 EM.
Histo-and immunochemistry
Transverse sections of the gastrocnemius, soleus, TA and EDL were stained with haematoxylin-eosin and labelled for myofibrillar ATPase by standard methods. Mice were intraperitonally (46) .
Antibodies
The following primary antibodies were used: rat anti-perlecan domain IV (MAB1948, Chemicon International), rabbit anti-perlecan domains I and V (kindly provided by the late Professor R. Timpl), rabbit anti-agrin (gift from Professor Dr MA Rüegg), rat anti-laminin-2 (4H8-2, Sigma-Aldrich), mouse anti-dystrophin (MANDRA1, Sigma-Aldrich), mouse anti-g-sarcoglycan (35DAG/21B5, Novocastra Laboratories), mouse anti a-dystroglycan (VIA4-1, Novocastra Laboratories), mouse anti-b-dystroglycan (NCL-b-DG, Novocastra Laboratories), rabbit anti-laminin a5 (gift from Dr J.H. Miner), mouse anti-syntrophin (1351, Affinity Bioreagents), mouse anti-SV2 (Developmental Studies Hybridoma Bank), mouse anti-2H3 (Developmental Studies Hybridoma Bank), mouse anti-rapsyn (1234, Affinity Bioreagents), rabbit anti-MuSK (Affinity Bioreagents), mouse anti-utrophin (clone DRP3/20C4, Novocastra Laboratories), mouse anti-neurofilament 200 (NE14, SigmaAldrich), mouse anti-synaptophysin (SVP-38, Sigma-Aldrich), mouse anti a-actinin (A7811, Sigma-Aldrich) and rabbit anti-S100 (Z0311, DakoCytomation). The fluorescein isothiocyanate (FITC)-, Texas Red (TR)-and Cy3-conjugated secondary antibodies were obtained from Jackson ImmunoResearch Laboratories. Biotinylated fasciculin-2 and Alexa 488-conjugated streptavidin (Molecular Probes, Invitrogen Detection Technologies) were used to label AChE. NMJs were counterstained with tetramethylrhodamine (TRITC) or FITCconjugated a-BTX.
Electromyography
All recordings were made with a standard EMG apparatus (Dantec, Les Ulis, France) in accordance with the guidelines of the American Association of Electrodiagnostic Medicine. Six and 10-month-old mice (n ¼ 12 for mutants and n ¼ 10 for controls) were anaesthetized with 1 mg/kg ketamine chlorhydrate and 0.5 mg/kg xylazine. A monopolar needle electrode (diameter, 0.3 mm; 9013R0312; Medtronic) was inserted into the tail of the mouse to ground the system. Recordings were made with a concentric needle electrode (diameter, 0.3 mm; 9013S0011; Medtronic). Muscles were monitored on both sides (right and left) for at least 2 min. Ten supramaximal nerve stimulations at slow rate (3 Hz) were applied to the sciatic nerve and the motor unit action potential (MUAP) was recorded to search for decrementing responses to repetitive stimulation. A sixth response 10% weaker than the first response was considered pathological. A more drastic protocol was also applied in which MUAPs were recorded in response to five supramaximal nerve stimulations at low frequency (3 Hz) after a series of three sets of 100 supramaximal stimulations at high frequency (30 Hz).
Isometric tension analyses
The contractile properties of the TA in situ and of isolated phrenic nerve-hemidiaphragm preparations ex vivo were studied as previously described (27, 28, 47) . Fatigue resistance was measured as the time taken for submaximal tetanic force to decrease by 20% during prolonged stimulation at 50 Hz. For TA, muscle tension was recorded in the same muscle in response to nerve stimulation, then in response to direct muscle stimulation after blockade of neuromuscular transmission with intramuscular injection of 30 ml of gallamine triethiodide (20 mg/ml), a synthetic non-depolarizing drug. PBS was injected as control in the controlateral muscle. To determine the contractile force for hemidiaphragms stimulated directly, a bath of 4 ml with an electrode array placed on each side of the muscle was used. Under this condition, neuromuscular transmission was blocked with 10 mM tubocurarine to avoid any pre-synaptic stimulation influence on the muscle tension recordings. The force-time integrals were calculated from twitch force signals using the software kindly provided by Dr John Dempster (Department of Physiology and Pharmacology, University of Strathclyde, Scotland).
Ex vivo electrophysiological studies
Electrophysiological recordings were carried out with conventional techniques (48) . Isolated hemidiaphragm muscles were mounted in thermoregulated and oxygenated standard physiological solution [154 mM NaCl, 5 mM KCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 5 mM N-2-hydroxyethylpiperazine-N 0 -2-ethanesulfonic acid (HEPES) and 11 mM glucose, pH 7.4]. Membrane and synaptic potentials were recorded from endplate regions at 31 + 18C with intracellular microelectrodes (filled with 3 M KCl solution, 8-12 MV resistance) and an Axoclamp-2A system (Axon Instruments). The distal part of the phrenic nerve was stimulated by a suction electrode with current pulses of 0.1 ms duration and a supramaximal voltage (typically 3 -8 V) at 0.1 Hz unless otherwise specified. Electrical signals were collected after amplification and digitized at a sampling rate of 25 kHz with a computer equipped with an analogueto-digital interface board (Digidata 1200, Axon Instruments), using software kindly provided by Dr John Dempster. Studies on nerve-evoked EPPs were performed in standard physiological solution containing 1.6 mM m-conotoxin-GIIIB (Alomone Labs, Jerusalem, Israel), a selective muscle Na þ channel blocker, to inhibit the generation of muscle action potentials (49) . The amplitudes of full-sized EPPs and MEPPs recorded on NMJs were normalized to a membrane potential of 275 mV. EPP amplitudes were corrected for non-linear summation (50) . The quantal content of full-sized EPPs was calculated at each NMJ by the direct method, by dividing the mean normalized and corrected EPP amplitude by the mean normalized MEPP amplitude. Giant MEPPs were excluded from the amplitude analysis as they did not contribute to the evoked EPPs. We generally used 20 consecutive EPPs and 50-80 MEPPs in the calculations. Preparations were equilibrated by incubation for 60 min with 3 mM neostigmine methylsulphate (France Biochem) for studies of AChE inhibition.
Statistical analyses
Data are expressed as the mean + SEM. The Student's t-test (two-tailed), x 2 test, Mann -Whitney rank sum test, log rank test and Kolmogorov -Smirnov two-sample test were used to determine the statistical significance of differences between control and mutant values. Differences were considered significant when P , 0.05.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online. 
